Skip to content

Adaptive Biotechnologies

US · ADPT #2184 by market cap Listed 2019
27.93 -0.12 -0.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 26.67 Expensive vs history 94th percentile
5-year average 6.50 · #38 of 41 in Diagnostics & Research
P/E ratio -64.53 Cheap vs history 4th percentile
5-year average -15.33 · forward -261.97
P/S ratio 15.77 Expensive vs history 95th percentile
5-year average 7.95 · forward 13.44 · #36 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Adaptive Biotechnologies (ADPT) 4.52B -62.07 25.65 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value22.74 Economic moatNone UncertaintyHigh

Trading 18.6% above Morningstar's fair value estimate.

Fair value

Adaptive Biotechnologies Corp earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 28% premium over our quantitative fair value estimate of $22.74 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's lack of profitability undermines our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 277.2, which lies in the top 10% compared with peers globally. This suggests limited cash flow is available for reinvestment or return to shareholders, which contributes to our view that shares are overvalued.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 3.9%, for example, falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adaptive Biotechnologies discussion 0 comments

Add a comment